933 reports of this reaction
4.6% of all REMDESIVIR reports
#2 most reported adverse reaction
ALANINE AMINOTRANSFERASE INCREASED is the #2 most commonly reported adverse reaction for REMDESIVIR, manufactured by Gilead Sciences, Inc.. There are 933 FDA adverse event reports linking REMDESIVIR to ALANINE AMINOTRANSFERASE INCREASED. This represents approximately 4.6% of all 20,319 adverse event reports for this drug.
Patients taking REMDESIVIR who experience alanine aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALANINE AMINOTRANSFERASE INCREASED is moderately reported among REMDESIVIR users, representing a notable but not dominant share of adverse events.
In addition to alanine aminotransferase increased, the following adverse reactions have been reported for REMDESIVIR:
The following drugs have also been linked to alanine aminotransferase increased in FDA adverse event reports:
ALANINE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 933 FDA reports for REMDESIVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALANINE AMINOTRANSFERASE INCREASED accounts for approximately 4.6% of all adverse event reports for REMDESIVIR, making it one of the most commonly reported side effect.
If you experience alanine aminotransferase increased while taking REMDESIVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.